Pacira BioSciences Inc (NASDAQ:PCRX) price on Friday, May 02, fall -1.12% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $26.45.
A look at the stock’s price movement, the close in the last trading session was $26.75, moving within a range at $26.1559 and $27.335. The beta value (5-Year monthly) was 0.708. Turning to its 52-week performance, $31.67 and $11.16 were the 52-week high and 52-week low respectively. Overall, PCRX moved 6.27% over the past month.
Pacira BioSciences Inc’s market cap currently stands at around $1.22 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-26.
Analysts have a consensus estimate of 175.88M for the company’s revenue for the quarter, with a low and high estimate of 173.9M and 179.38M respectively. The average forecast suggests up to a 5.24% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 752.94M, representing a 7.41% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PCRX is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 5 recommend PCRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PCRX’s current price about 4.16% and 7.46% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.88, while 7-day volatility ratio is 3.98% and 5.77% in the 30-day chart. Further, Pacira BioSciences Inc (PCRX) has a beta value of 0.55, and an average true range (ATR) of 1.29. Analysts have given the company’s stock an average 52-week price target of $24.5, forecast between a low of $12 and high of $48. Looking at the price targets, the low is 54.63% off current price level while to achieve the yearly target high, price needs to move -81.47%. Nonetheless, investors will most likely welcome a 7.37% jump to $24.5 which is the analysts’ median price.
If we refocus on Pacira BioSciences Inc (NASDAQ:PCRX), historical trading data shows that trading volumes averaged 0.77 over the past 10 days and 898.78K over the past 3 months. The company’s latest data on shares outstanding shows there are 46.24 million shares.
The 4.38% of Pacira BioSciences Inc’s shares are in the hands of company insiders while institutional holders own 107.16% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.06 million on 2025-04-15, giving us a short ratio of 5.49. The data shows that as of 2025-04-15 short interest in Pacira BioSciences Inc (PCRX) stood at 1904.9999 of shares outstanding, with shares short rising to 5.93 million registered in 2025-03-14. Current price change has pushed the stock 40.39% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PCRX stock continues to rise going into the next quarter.
